Literature DB >> 19383908

B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells.

Mirijam Mannefeld1, Elena Klassen, Stefan Gaubatz.   

Abstract

In response to DNA damage, several signaling pathways that arrest the cell cycle in G(1) and G(2) are activated. The down-regulation of mitotic genes contributes to the stable maintenance of the G(2) arrest. The human LINC or DREAM complex, together with the B-MYB transcription factor, plays an essential role in the expression of G(2)-M genes. Here, we show that DNA damage results in the p53-dependent binding of p130 and E2F4 to LINC and the dissociation of B-MYB from LINC. We find that B-MYB fails to dissociate from LINC in p53 mutant cells, that this contributes to increased G(2)-M gene expression in response to DNA damage in these cells, and, importantly, that B-MYB is required for recovery from the G(2) DNA damage checkpoint in p53-negative cells. Reanalysis of microarray expression data sets revealed that high levels of B-MYB correlate with a p53 mutant status and an advanced tumor stage in primary human breast cancer. Taken together, these data suggest that B-MYB/LINC plays an important role in the DNA damage response downstream of p53.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383908     DOI: 10.1158/0008-5472.CAN-08-4156

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Recovery from a DNA-damage-induced G2 arrest requires Cdk-dependent activation of FoxM1.

Authors:  Mónica Alvarez-Fernández; Vincentius A Halim; Lenno Krenning; Melinda Aprelia; Shabaz Mohammed; Albert J Heck; René H Medema
Journal:  EMBO Rep       Date:  2010-04-09       Impact factor: 8.807

2.  CK2 kinase activity but not its binding to CK2 promoter regions is implicated in the regulation of CK2α and CK2β gene expressions.

Authors:  Sarah Lupp; Catalina Gumhold; Emmanuel Ampofo; Mathias Montenarh; Karen Rother
Journal:  Mol Cell Biochem       Date:  2013-08-21       Impact factor: 3.396

3.  Cathepsin L induced PC-12 cell apoptosis via activation of B-Myb and regulation of cell cycle proteins.

Authors:  Xiao Shen; Yi-Fan Zhao; Shu-Qing Xu; Long Wang; Hui-Min Cao; Ying Cao; Ying Zhu; Yan Wang; Zhong-Qin Liang
Journal:  Acta Pharmacol Sin       Date:  2019-08-23       Impact factor: 6.150

4.  E2 Ubiquitin-conjugating Enzyme, UBE2C Gene, Is Reciprocally Regulated by Wild-type and Gain-of-Function Mutant p53.

Authors:  Swati Bajaj; Sk Kayum Alam; Kumar Singha Roy; Arindam Datta; Somsubhra Nath; Susanta Roychoudhury
Journal:  J Biol Chem       Date:  2016-04-28       Impact factor: 5.157

5.  Downregulation of B-myb promotes senescence via the ROS-mediated p53/p21 pathway, in vascular endothelial cells.

Authors:  Zhihui Zhou; Yanlin Yin; Qun Chang; Guanqun Sun; Jiahui Lin; Yalei Dai
Journal:  Cell Prolif       Date:  2016-11-23       Impact factor: 6.831

Review 6.  Cell type- and species-specific host responses to Toxoplasma gondii and its near relatives.

Authors:  Zhee S Wong; Sarah L Sokol Borrelli; Carolyn C Coyne; Jon P Boyle
Journal:  Int J Parasitol       Date:  2020-05-11       Impact factor: 3.981

Review 7.  B-Myb, cancer, senescence, and microRNAs.

Authors:  Ivan Martinez; Daniel Dimaio
Journal:  Cancer Res       Date:  2011-08-09       Impact factor: 12.701

8.  Transcriptional regulation underlying recovery from a DNA damage-induced arrest.

Authors:  Mónica Alvarez-Fernández; René H Medema; Arne Lindqvist
Journal:  Transcription       Date:  2010 Jul-Aug

Review 9.  Interplay between HMGA and TP53 in cell cycle control along tumor progression.

Authors:  Nathalia Meireles Da Costa; Antonio Palumbo; Marco De Martino; Alfredo Fusco; Luis Felipe Ribeiro Pinto; Luiz Eurico Nasciutti
Journal:  Cell Mol Life Sci       Date:  2020-09-12       Impact factor: 9.261

10.  Tousled-like kinase 2 regulates recovery from a DNA damage-induced G2 arrest.

Authors:  Wytse Bruinsma; Jeroen van den Berg; Melinda Aprelia; René H Medema
Journal:  EMBO Rep       Date:  2016-03-01       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.